poisar

Stocks · News reference

OmniAb Announces Global Collaboration and License Agreement with Eli Lilly For New Ion Channel Program; OmniAb To Receive An Upfront Payment and Is Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments

Benzinga Newsdesk

The therapeutic target and modality are undisclosed.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LLYOABI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Nxera Pharma

    Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress

    Nxera Pharma announced it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals (a subsidiary of Eli Lilly) following late-stage development progress on selective orexin receptor 2 (OX2R) agonist candidates. The payment will be recognized as revenue in Q3 2026. Nxera retains rights to future development, commercialization milestones, and royalties from the OX2R agonist programs.

    LLY
  3. Na

    HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss

    Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.

    HIMSNVOLLY
  4. Robert Izquierdo

    Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

    Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.

    FHLCIBBQLLYJNJABBV